137 related articles for article (PubMed ID: 28570008)
41. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
42. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.
Kang EY; Millstein J; Popovic G; Meagher NS; Bolithon A; Talhouk A; Chiu DS; Anglesio MS; Leung B; Tang K; Lambie N; Pavanello M; Da-Anoy A; Lambrechts D; Loverix L; Olbrecht S; Bisinotto C; Garcia-Donas J; Ruiz-Llorente S; Yagüe-Fernandez M; Edwards RP; Elishaev E; Olawaiye A; Taylor S; Ataseven B; du Bois A; Harter P; Lester J; Høgdall CK; Armasu SM; Huang Y; Vierkant RA; Wang C; Winham SJ; Heublein S; Kommoss FKF; Cramer DW; Sasamoto N; van-Wagensveld L; Lycke M; Mateoiu C; Joseph J; Pike MC; Odunsi K; Tseng CC; Pearce CL; Bilic S; Conrads TP; Hartmann A; Hein A; Jones ME; Leung Y; Beckmann MW; Ruebner M; Schoemaker MJ; Terry KL; El-Bahrawy MA; Coulson P; Etter JL; LaVigne-Mager K; Andress J; Grube M; Fischer A; Neudeck N; Robertson G; Farrell R; Barlow E; Quinn C; Hettiaratchi A; Casablanca Y; Erber R; Stewart CJR; Tan A; Yu Y; Boros J; Brand AH; Harnett PR; Kennedy CJ; Nevins N; Morgan T; Fasching PA; Vergote I; Swerdlow AJ; Candido Dos Reis FJ; Maxwell GL; Neuhausen SL; Barquin-Garcia A; Modugno F; Moysich KB; Crowe PJ; Hirasawa A; Heitz F; Karlan BY; Goode EL; Sinn P; Horlings HM; Høgdall E; Sundfeldt K; Kommoss S; Staebler A; Wu AH; Cohen PA; DeFazio A; Lee CH; Steed H; Le ND; Gayther SA; Lawrenson K; Pharoah PDP; Konecny G; Cook LS; Ramus SJ; Kelemen LE; Köbel M
Virchows Arch; 2022 Apr; 480(4):855-871. PubMed ID: 34782936
[TBL] [Abstract][Full Text] [Related]
43. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
44. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
Köbel M; Kang EY
Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
[TBL] [Abstract][Full Text] [Related]
45. Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.
Dieters-Castator DZ; Rambau PF; Kelemen LE; Siegers GM; Lajoie GA; Postovit LM; Köbel M
Clin Cancer Res; 2019 Jul; 25(14):4309-4319. PubMed ID: 30979743
[TBL] [Abstract][Full Text] [Related]
46. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
47. High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis.
Hatano Y; Fukuda S; Makino H; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2018 Apr; 13(1):24. PubMed ID: 29703236
[TBL] [Abstract][Full Text] [Related]
48. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
49. Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.
Tessier-Cloutier B; Cochrane DR; Karnezis AN; Colborne S; Magrill J; Talhouk A; Zhang J; Leung S; Hughes CS; Piskorz A; Cheng AS; Greening K; du Bois A; Pfisterer J; Soslow RA; Kommoss S; Brenton JD; Morin GB; Gilks CB; Huntsman DG; Kommoss F
Hum Pathol; 2020 Jul; 101():40-52. PubMed ID: 32360491
[TBL] [Abstract][Full Text] [Related]
50. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
51. Immunophenotypic Analysis in Early Müllerian Serous Carcinogenesis.
Nafisi H; Ghorab Z; Ismill N; Dubé V; Plotkin A; Han G; Cesari M; Lu FI; Saad R; Khalifa M; Nofech-Mozes S
Int J Gynecol Pathol; 2015 Sep; 34(5):424-36. PubMed ID: 26107560
[TBL] [Abstract][Full Text] [Related]
52. WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis.
Stewart CJ; Brennan BA; Chan T; Netreba J
Pathology; 2008 Oct; 40(6):592-9. PubMed ID: 18752126
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
[TBL] [Abstract][Full Text] [Related]
54. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
[TBL] [Abstract][Full Text] [Related]
55. Cardiophrenic Lymph Node Metastasis of Ovarian High-grade Serous Carcinoma Showing Wild-type p53 Immunostaining Pattern and Aberrant CD56 Expression.
Kwon HJ; Oh M; Han J; Song SY; Kim HS
Int J Surg Pathol; 2021 Dec; 29(8):864-869. PubMed ID: 33764173
[TBL] [Abstract][Full Text] [Related]
56. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
[TBL] [Abstract][Full Text] [Related]
57. Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience.
Lee S; Piskorz AM; Le Page C; Mes Masson AM; Provencher D; Huntsman D; Chen W; Swanson PE; Gilks CB; Köbel M
Int J Gynecol Pathol; 2016 May; 35(3):209-21. PubMed ID: 26598982
[TBL] [Abstract][Full Text] [Related]
58. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
[TBL] [Abstract][Full Text] [Related]
59. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
[TBL] [Abstract][Full Text] [Related]
60. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
Dos Santos MV; Holth A; Bischof K; Davidson B
Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
